Biotech · Private company
Forma Therapeutics, Inc.
Track this companyFree. Adds Forma Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials81 recruiting or active
Pipeline programs14From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline14
- Etavopivat TabletsPhase 3 · Sickle Cell DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Etavopivat Tablets High dosePhase 3 · Sickle Cell DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Etavopivat Tablets Low dosePhase 3 · Sickle Cell DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- AzacitidinePhase 2 · Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme)ClinicalTrials.gov · fetched Nov 12, 2026
- AzacitidinePhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- CytarabinePhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Deuterated WaterPhase 2 · Nonalcoholic Steatohepatitis (NASH)ClinicalTrials.gov · fetched Nov 12, 2026
- EtavopivatPhase 2 · Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-RClinicalTrials.gov · fetched Nov 12, 2026
- FT-2102Phase 2 · Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme)ClinicalTrials.gov · fetched Nov 12, 2026
- FT-2102 (olutasidenib)Phase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- FT-4101Phase 2 · Nonalcoholic Steatohepatitis (NASH)ClinicalTrials.gov · fetched Nov 12, 2026
- Gemcitabine and CisplatinPhase 2 · Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme)ClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 2 · Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme)ClinicalTrials.gov · fetched Nov 12, 2026
- FT-1101Phase 1 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)PHASE2 · TERMINATED · started Nov 15, 2022ClinicalTrials.gov NCT05568225 · fetched Nov 12, 2026
- A Study of Etavopivat in Patients With Thalassemia or Sickle Cell DiseasePHASE2 · COMPLETED · started Mar 28, 2022ClinicalTrials.gov NCT04987489 · fetched Nov 12, 2026
- A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)PHASE3 · ACTIVE_NOT_RECRUITING · started Jan 29, 2021ClinicalTrials.gov NCT04624659 · fetched Nov 12, 2026
- A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic SteatohepatitisPHASE1_PHASE2 · TERMINATED · started May 17, 2019ClinicalTrials.gov NCT04004325 · fetched Nov 12, 2026
- A SAD/MAD to Assess the Safety, PK/PD of FT-4202 in Healthy Volunteers and Sickle Cell Disease PatientsPHASE1 · COMPLETED · started Dec 11, 2018ClinicalTrials.gov NCT03815695 · fetched Nov 12, 2026
- A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 MutationPHASE1_PHASE2 · COMPLETED · started Nov 1, 2018ClinicalTrials.gov NCT03684811 · fetched Nov 12, 2026
- Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 MutationPHASE1_PHASE2 · COMPLETED · started Apr 30, 2016ClinicalTrials.gov NCT02719574 · fetched Nov 12, 2026
- Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic MalignanciesPHASE1 · COMPLETED · started Sep 1, 2015ClinicalTrials.gov NCT02543879 · fetched Nov 12, 2026